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Abstract Saliva is a readily accessible and informative
bioﬂuid, making it ideal for the early detection of a wide
range of diseases including cardiovascular, renal, and
autoimmune diseases, viral and bacterial infections and,
importantly, cancers. Saliva-based diagnostics, particularly
those based on metabolomics technology, are emerging and
offer a promising clinical strategy, characterizing the
association between salivary analytes and a particular dis-
ease. Here, we conducted a comprehensive metabolite
analysis of saliva samples obtained from 215 individuals
(69 oral, 18 pancreatic and 30 breast cancer patients, 11
periodontal disease patients and 87 healthy controls) using
capillary electrophoresis time-of-ﬂight mass spectrometry
(CE-TOF-MS). We identiﬁed 57 principal metabolites that
can be used to accurately predict the probability of being
affected by each individual disease. Although small but
signiﬁcant correlations were found between the known
patient characteristics and the quantiﬁed metabolites, the
proﬁles manifested relatively higher concentrations of most
of the metabolites detected in all three cancers in com-
parison with those in people with periodontal disease and
control subjects. This suggests that cancer-speciﬁc signa-
tures are embedded in saliva metabolites. Multiple logistic
regression models yielded high area under the receiver-
operating characteristic curves (AUCs) to discriminate
healthy controls from each disease. The AUCs were 0.865
for oral cancer, 0.973 for breast cancer, 0.993 for pancre-
atic cancer, and 0.969 for periodontal diseases. The accu-
racy of the models was also high, with cross-validation
AUCs of 0.810, 0.881, 0.994, and 0.954, respectively.
Quantitative information for these 57 metabolites and their
combinations enable us to predict disease susceptibility.
These metabolites are promising biomarkers for medical
screening.
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1 Introduction
Saliva is an important biological ﬂuid that provides various
functions, including lubrication for speech, digestion of
food, and protection from microorganisms. It is produced
by multiple salivary glands; particularly the three major
salivary glands parotid, submandibular and sublingual, and
several minor glands. Saliva is comprised of 99% water
with minerals, mucus, electrolytes, nucleic acids and pro-
teins such as enzymes, enzyme inhibitors, growth factors,
cytokines, immunoglobulins, and other glycoproteins (de
Almeida Pdel et al. 2008). Saliva is a ﬁltration of blood,
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could be used to monitor clinical status and predict sys-
temic diseases. Compared with blood, saliva offers distinct
advantages for diagnostic or research purposes; its collec-
tion is cost-effective, safe, easy and non-invasive. Indeed,
many of the characteristics of bodily ﬂuids, such as blood
and urine, are applicable to saliva including diurnal vari-
ation and the presence of diverse diagnostic analytes.
Cancer is a leading cause of death and oral cancer
annually affects more than 400,000 individuals worldwide.
Despite advances in treatment, the overall 5-year survival
rate of patients with oral cancer is approximately 50% and
has not improved over the past 30 years (Epstein et al.
2002; Mao et al. 2004). The mortality rate associated with
oral cancer is particularly high because it is routinely dis-
covered late, commonly after metastasis to the lymph
nodes or neck has already occurred. Worldwide, more than
200,000 patients with pancreatic cancer are registered
annually, and 98% of the patients die of the disease (Parkin
et al. 2005). The high mortality rate from this cancer is
thought to be due to a lack of adequate systemic therapies
and the high rate of metastasis at the time of diagnosis.
Therefore, novel diagnostic tests are urgently needed to
detect these cancers at the premalignant stage.
Studies using molecular-based biomarkers in blood or
urine to detect the progress of malignant tumors have
mainly focused on altered DNA methylation or mutation,
or on changes in the RNA or protein levels (Sidransky
2002). In addition, several molecular biomarker candidates
have been identiﬁed by analyzing the transcriptome or
proteome of saliva (Hu et al. 2007, 2008; Zimmermann and
Wong 2008). However, sufﬁciently sensitive and repro-
ducible saliva-based diagnostic methods are not yet avail-
able. In addition, conventional tumor markers, such as
serum cancer antigen 19-9, which is widely used in the
diagnosis of pancreatic cancer, are known to have less
speciﬁcity for particular lesions. With the exception of
breast cancer (Streckfus et al. 2008), few studies have used
saliva to detect tumors remote from the oral cavity. Tumor
markers that can discriminate individual cancer-speciﬁc
differences and which are sensitive are required for clinical
applications.
Metabolomics, the measurement of all intracellular
metabolites, has become a powerful new tool to gain
insight into cellular function. So far, several metabolomic
approaches have been reported (Aharoni et al. 2002; Fiehn
et al. 2000; Plumb et al. 2003; Reo 2002). In this marriage
of methodologies, CE offers rapid analysis and efﬁcient
resolution, and MS provides excellent selectivity and sen-
sitivity (Soga et al. 2006). A number of clinical applica-
tions of CE-MS exploring urinary or serum proteomics
biomarkers, were developed to detect and identify the
charged peptide content, which demonstrates their potential
to assess the proﬁles of small molecules in bioﬂuids (Fliser
et al. 2005; Kolch et al. 2005; Metzger et al. 2009; Schiffer
et al. 2006, 2008; Zurbig and Mischak 2008). Although
diverse saliva analyses with CE have been proposed (Lloyd
2008), salivary metabolomic analysis to determine cancer-
speciﬁc proﬁles for early cancer detection has not yet been
conducted. In this study, we, for the ﬁrst time, obtained and
compared comprehensive salivary metabolic proﬁles of
patients with oral, breast or pancreatic cancer, or peri-
odontal disease, and healthy controls. We then identiﬁed
individual cancer-speciﬁc markers with high discriminative
ability, demonstrating the potential use of salivary meta-
bolomics in cancer diagnosis.
2 Materials and methods
2.1 Patient selection
This study was approved by the UCLA Institutional
Review Board. Patients with oral, breast or pancreatic
cancer or periodontal disease and the healthy controls were
recruited at the UCLA Medical Center. All patients had
recently been diagnosed with primary disease and were
without metastasis; none had received any prior treatment
in the form of chemotherapy, radiotherapy, surgery or
alternative therapy. No subjects had a history of prior
malignancy, immunodeﬁciency, autoimmune disorders,
hepatitis or HIV infection. Written, informed consent was
obtained from all patients and from volunteers who agreed
to serve as saliva donors.
2.2 Sample collection and sample preparation
The subjects were asked to refrain from eating, drinking,
smoking or using oral hygiene products for at least 1 h
prior to saliva collection. The subjects rinsed their mouth
with water and, 5 min later, they were instructed to spit
into 50-cc Falcon tubes, which were placed in a Styrofoam
cup ﬁlled with crushed ice. The subjects were reminded not
to cough up mucus. Five milliliters of unstimulated saliva
could usually be collected in 5–10 min. Saliva collection
was performed in a private room. The saliva samples were
centrifuged at 26009g for 15 min at 4C and spun for
another 20 min for incomplete separation. Equal amounts
of supernatant were transferred to two fresh tubes and the
samples were processed and frozen within 30 min. The
protocols used for sample collection are described in more
detail elsewhere (Li et al. 2004).
Saliva ﬂuid samples were obtained from patients with
oral (n = 69), breast (n = 30) and pancreatic cancer
(n = 18), patients with periodontal diseases (n = 11) and
healthy controls (n = 87). The race, ethnicity, sex and age
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clinical parameters were not collected for the non-oral
cancer groups.
Frozen saliva was thawed and dissolved at room tem-
perature, and 27 ll of each sample (69 patients with oral
cancer and 70 healthy control samples) were added to a
1.5-ml Eppendorf tube, to which 3 ll of water containing
2 mM methionine sulfone and 2 mM 3-aminopyrrolidine
as internal standards was added and mixed well. Similarly,
individual thawed saliva samples (24 ll) from patients
with breast or pancreatic cancer, and patients with peri-
odontal disease and 17 healthy controls were admixed with
6 ll water containing internal standards (1 mM each of
methionine sulfone and 3-aminopyrrolidine). These inter-
nal standards were selected because they were not included
in the human endogenetic metabolites. Furthermore, they
migrated to the center of the metabolite distribution, which
was used to conﬁrm the quality of the alignment results.
Even though a uniﬁed dilution was preferred for the
preparation of all samples, a greater dilution ratio was
required for the control, breast, pancreatic cancer, and
periodontal disease samples because of their high electro-
lyte content, which decreases the electrical current during
the measurement.
2.3 Metabolite standards, instrumentation,
and CE-TOF-MS conditions
The metabolite standards, instrumentation and CE-TOF-
MS condition were used in this study as previously
described (Soga et al. 2006), with slight modiﬁcations in
the lock mass system setting. All chemical standards were
of analytical or reagent grade and were obtained from
commercial sources. They were dissolved in Milli-Q water
(Millipore, Bedford, MA, USA), 0.1 mol/l HCl or 0.1 mol/
l NaOH to obtain 1, 10 or 100 mmol/l stock solutions. The
working solution was prepared prior to use by diluting with
Milli-Q water to the appropriate concentration.
All CE-MS experiments were performed using an Agi-
lent CE capillary electrophoresis system (Agilent Tech-
nologies, Waldbronn, Germany), an Agilent G3250AA LC/
MSD TOF system (Agilent Technologies, Palo Alto, CA,
USA), an Agilent 1100 series binary HPLC pump, and the
G1603A Agilent CE-MS adapter and G1607A Agilent CE-
ESI-MS sprayer kit. System control and data acquisition
were done with G2201AA Agilent Chemstation software
for CE and Analyst QS software for TOF-MS (ver. 1.1).
All samples were measured in single mode (see below);
separation was done in fused-silica capillaries (50 lm
i.d. 9 100 cm total length) ﬁlled with 1 M formic acid as
the background electrolyte. Sample solutions were injected
at 50 mbar for 3 s and a voltage of 30 kV was applied. The
capillary temperature was maintained at 20C and the
temperature of the sample tray was kept below 5C using
an external thermostatic cooler. The sheath liquid, com-
prising methanol/water (50% v/v) and 0.5 lM reserpine,
was delivered at 10 ll/min. ESI-TOF-MS was conducted
in the positive ion mode. The capillary voltage was set at
4 kV; the ﬂow rate of nitrogen gas (heater temperature
300C) was set at 10 psig. In TOF-MS, the fragmentor,
skimmer and OCT RFV voltage were set at 75, 50 and
125 V, respectively. In the present study, we used a
methanol dimer adduct ion ([2MeOH ? H]
?, m/z
65.059706) and hexakis phosphazene ([M ? H]
?, m/z
Table 1 Subject characteristics
Groups Control Oral cancer Breast cancer Pancreatic cancer Periodontal diseases
Age
Min–Max (median) 20–75 (43) 34–87 (59.5) 29–77 (57) 11–87 (67) 23–76 (60)
Missing 2 5 10 2 2
Sex
Male 42 41 N/A
Female 27 23
Missing 18 5 30 18 11
Race or ethnic group
Total 87 69 30 18 11
Caucasian 37 41 N/A
Asia 15 5
African-American 12 4
Hispanic 5 5
Missing 18 14 30 18 11
N/A not available
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123622.028963) to provide the lock mass for exact mass
measurements. Exact mass data were acquired at the rate of
1.5 cycles/s over a 50–1000 m/z range.
2.4 Processing of CE-TOF-MS data
Raw data were analyzed with our proprietary software
called MasterHands, which has already been used in sev-
eral CE-TOF-MS-based proﬁling studies (Hirayama et al.
2009; Minami et al. 2009; Saito et al. 2009). The data
analysis workﬂow starting with the raw data included
noise-ﬁltering, baseline correction, peak detection and
integration of the peak area from sliced electropherograms
(the width of each electropherogram was 0.02 m/z). Such
functions are commonly used by data processing software
such as MassHunter from Agilent Technologies, or XCMS
(Smith et al. 2006) for liquid chromatography-MS or gas
chromatography-MS data. The accurate m/z value for each
peak detected within the time domain was calculated with
Gaussian curve-ﬁtting to the mass spectrum on the m/z
domain peak. The alignment of peaks in multiple mea-
surements was done by dynamic programming (DP)-based
techniques (Baran et al. 2006; Soga et al. 2006) with slight
modiﬁcations. The method picked up a few representative
peaks using the Douglas-Peucker algorithm (Wallace et al.
2004) from unit m/z electropherograms, found corre-
sponding peaks across multiple samples by DP, and opti-
mized the numerical parameters of the normalization
function for CE-migration (Reijenga et al. 2002). Instead of
representative peaks, we used the detected peaks with
accurate m/z values and regarded the peaks whose m/z
difference was less than 20 ppm as ones that were derived
from the same electropherograms.
All peak areas were divided by the area of the internal
standard (relative area) to normalize the signal intensities,
and to avoid injection-volume bias and mass-spectrometry
detector sensitivity bias among multiple measurements.
Undetected peaks with a threshold signal-to-noise ratio of 2
were given a peak area of 0. The relative areas of the 17
healthy control samples and of the pancreatic and breast
cancer, and the periodontal disease samples were multi-
plied by 1.25/1.1 to standardize the sample concentration.
The peaks derived from salt and neutral molecules were
found in the ﬁrst and the last few minutes, respectively.
Then, isotopic compounds, ringing, spikes and fragment
and adduct ions were eliminated and the peak data sets
were compared across the sample proﬁles and aligned
according to m/z and migration time. Although all of the
metabolites were quantiﬁed separately, the sum of the
quantiﬁed values of leucine and isoleucine were counted as
a single marker owing to the low separation of these peaks.
Peaks showing P\0.05 in the non-parametric, multiple
comparison Steel–Dwass test, between the controls and at
least one disease cohort were selected as candidate
markers.
2.5 Metabolite identiﬁcation
The peaks were identiﬁed based on the matched m/z values
and normalized migration times of the corresponding
standard compounds if available. Of the peaks that did not
match with any standard compounds, the concomitant
peaks, such as isotopic peaks and fragment peaks, were
removed based on the difference in m/z values and the
normalized migration time of the two peaks with an error
tolerance of 20 ppm and 0.01 min to yield only the peaks,
or referred to as components, which might be derived from
metabolites (Brown et al. 2009). Although CE-TOF-MS
provides accurate molecular mass at the milli m/z level, the
m/z alone is seldom successful to identify the metabolite
(Kind and Fiehn 2006, 2007). Therefore, we used their m/z
values and the migration times predicted by the Artiﬁcial
Neural Networks (ANNs) (Sugimoto et al. 2005) to iden-
tify the metabolite. Brieﬂy, the ANN model was ﬁrst
trained using the measured migration times of standard
compounds and molecular descriptors with the net charge
calculated from the pKa values. The trained ANN model
then predicted the migration times of the candidate
metabolites. Here, we used compounds available from the
Kyoto Encyclopedia of Gene and Genomics (KEGG)
database (Goto et al. 2002) and the Human Metabolome
Database (HMDB) (Wishart et al. 2007) as candidates. The
composition formulae obtained using the measured mass
spectrometry and the matched candidates were conﬁrmed
by their isotope distribution patterns.
2.6 Statistical analysis
To evaluate the ability of the detected peaks to discriminate
diseases, we conducted an unsupervised method, principal
component analysis (PCA). The same analyses were also
conducted to discriminate only between controls and oral
samples between males and females, and between race and
ethnic groups. The analyses were not performed for the
other patient groups due to the unavailability of clinical
parameters. Supervised classiﬁcation techniques, such as
partial least squares-discriminant analysis (Jonsson et al.
2005; Michell et al. 2008; Woo et al. 2009), support vector
machine (SVM) (Mahadevan et al. 2008) and multiple
logistic regression (MLR), are commonly used to separate
subjects and to identify important features for the separa-
tion. Here, we developed independent MLR models to
discriminate healthy individuals and each disease cohort
using a stepwise variable selection method (backward
procedure to eliminate non-predictive peaks with a
threshold of P[0.10) to construct the predictive models.
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evaluated their versatilities by tenfold cross-validation
(CV). The data were randomly separated into training sets
and remaining data and this process was repeated ten times
for all of the values selected in the training set. The non-
parametric Mann–Whitney test was used to compare two
groups, e.g. comparison of metabolites in males and
females.
Statistical analyses using the Steel–Dwass test were
performed using the R package with the Design, Hmisc,
and Lexis libraries (available at http://lib.stat.cmu.edu/
R/CRAN/). Statistical analyses using the Mann–Whitney
test and the heat maps were generated with TM4 software
(Saeed et al. 2003). The CV data were generated using
WEKA (Witten and Frank 2005). The PCA and MLR
models were developed using JMP Version 7 (SAS Insti-
tute Inc., Cary, NC, USA, 1989–2007; http://www.jmp.
com/software/jmp.shtml).
3 Results and discussion
3.1 Statistical results of discriminative metabolites
On average, CE-TOF-MS detected 3041 peaks (minimum
1585, maximum 8400, standard deviation (SD) 1137) in
each saliva sample. After removing the concomitantly
observed peaks such as the isotopic and fragment peaks,
and noise peaks including spike and ringing peaks, an
average of 90 peaks were derived from the metabolites
(minimum 48, maximum 128, SD 15). The standard devi-
ation of the relative peak areas of the metabolite-derived
peaks was 1.14 (no unit), and the SDs of the migration
times before and after the time normalization procedure
were 1.75 min and 3.02 9 10
-3 min, respectively. Of the
remaining peaks, we identiﬁed 57 metabolites that were
signiﬁcantly different between the patients and healthy
controls (P\0.05; Steel–Dwass test).
The marker pool used to discriminate between individ-
uals with oral cancer and healthy controls revealed 28
metabolites; namely pyrroline hydroxycarboxylic acid,
leucine plus isoleucine, choline, tryptophan, valine, threo-
nine, histidine, pipecolic acid, glutamic acid, carnitine,
alanine, piperidine, taurine, and two other metabolites with
a signiﬁcance of P\0.001 (Steel–Dwass test); piperidine,
alpha-aminobutyric acid, phenylalanine and an additional
metabolite with a signiﬁcance of P\0.01 (Steel–Dwass
test); and betaine, serine, tyrosine, glutamine, beta-alanine,
cadaverine, and two other metabolite with a signiﬁcance of
P\0.05 (Steel–Dwass test). The overlaid electrophero-
grams of these CE-TOF-MS peaks with a 2-dimensional
map (migration time and m/z) visualizing the difference in
intensity between the averaged control and oral cancer
samples are shown in Fig. 1. The vertical smear lines in the
ﬁrst few minutes (5–7 min) and those at a later time (at
19 min) were derived from salt ions and neutral molecules,
respectively, and most of the peaks derived from charged
metabolites were distributed between these times. Using a
similar strategy, we identiﬁed 28 metabolites for breast
cancer, 48 for pancreatic cancer and 27 for periodontal
disease (P\0.05; Steel–Dwass test) as biomarker candi-
dates. The detected markers and the statistical results are
listed in Table 2; dot plots of the quantiﬁed peak areas are
shown in Fig. 2 and Supplementary Fig. S1. Although,
several metabolites in the dot plots achieved a statistically
signiﬁcant difference, individual metabolites could not
separate any two groups with high sensitivity and speci-
ﬁcity. The score plots of the PCA analyses for all indi-
viduals are shown in Fig. 3 and in Supplementary Fig. S2.
Although the PCA developed using the metabolite proﬁles
of all subjects showed no unequivocal group-speciﬁc
clusters, PCAs developed individually for the control and
each disease group showed partial discriminative separa-
tion of the subjects, which might be attributed to the
reduced complexity of the given datasets, or the extinction
in the overlap between the distribution of the score plots for
all disease groups.
The MLR model developed for oral cancer yielded a high
AUC (0.865), and the trained models also showed high
separation ability in the CV (AUC = 0.810). The receiver
operating characteristic (ROC) curves and selected param-
eters of the MLR models for each disease are shown in
Fig. 4 and Supplementary Table S1, respectively. The
MLR models for pancreatic cancer and periodontal disease
yielded high AUCs in the CV test (0.944 and 0.954,
respectively), using only ﬁve and two metabolic markers,
respectively; while oral and breast cancers (0.810 and
0.881, respectively) used 9 and 14 metabolites, respec-
tively, with lower AUCs. On the metabolite heat map
(Fig. 5), the control group and the periodontal disease group
were relatively lower and the pancreatic cancer group ten-
ded to be homologically higher, while the oral and breast
cancers exhibited more diverse proﬁles compared with the
other groups. This suggests that our MLR models for oral
and breast cancer require additional parameters for accurate
classiﬁcation. The heterogeneous nature of oral cancers,
including oral squamous cell carcinoma (OSCC), oropha-
ryngeal, tongue and neck cancer, may produce different
proﬁles; this diminishes the discriminative capability of a
single classiﬁcation model. The diverse proﬁles associated
with breast cancer may result in a similar situation because
breast cancer comprises structurally differing types
according to the expression of hormone receptors such as
estrogen and progesterone, and is affected by clinical
parameters, such as the patient’s age or menopause status.
Three metabolites, taurine, piperidine, and a peak at
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123120.0801 m/z, were oral cancer-speciﬁc markers (different
from all of the other groups at P\0.05; Steel–Dwass test)
and eight metabolites (leucine with isoleucine, tryptophan,
valine, glutamic acid, phenylalanine, glutamine, and
aspartic acid) were pancreatic cancer-speciﬁc markers.
Although several metabolites in breast cancer patients
yielded a statistically signiﬁcant difference between breast
cancer and healthy controls, including taurine and lysine
(P\0.001 for both; Steel–Dwass test), there were no dif-
ferences in metabolites between breast cancer and other
cancer, and they were not unique for breast cancer.
3.2 Comparison of the obtained metabolites
with previous studies
Of the metabolite proﬁles obtained, the annotated metab-
olites included carnitines (betaine, choline, carnitine,
glycerophosphocholine), polyamines (cadaverine and
putrescine), a purine (hypoxanthine), amino alcohols (eth-
anolamine), aliphatic and aromatic amine (trimethyla-
mine), and amino acids (the others), in accordance with the
deﬁned chemical class category in HMDB. Because each
MLR model developed to discriminate between control and
patient groups reached high accuracy by incorporating
quantiﬁed multiple metabolites, the quantitative associa-
tions between the multiple metabolites and the individual
markers are important. Changes in the individual metabo-
lites were generally consistent with those of earlier studies.
For example, polyamines are correlated with cell growth
and proliferation (Casero and Marton 2007; Gerner and
Meyskens 2004; Tabor and Tabor 1984), and with tumor
growth in oral cancer (Dimery et al. 1987), while putres-
cine is used to monitor the effect of chemotherapy on
oral cancer cells (Okamura et al. 2007). The serum
Glutamic acid
Pyrroline 
hydroxycarboxylic acid 
Choline
Alanine
Carnitine
Piperidine
139.0500 m/z
Betaine
Glutamine
Cadaverine
288.9691 m/z
beta-Alanine
145.1332 m/z 72.0813 m/z
Threonine
Pipecolic acid
Phenylalanine 
Piperideine
alpha-Aminobutyric acid
m
/
z
Migration time (min.)
Tyrosine
Tryptophan
Serine
Taurin
Valine
Leucine + Isoleucine
Histidine
120.0801 m/z
Fig. 1 A summary of the different metabolome proﬁles of cations
obtained from CE-TOF-MS analyses of salivary metabolites from
control (n = 87) and oral cancer samples (n = 69). The X and Y axes
represent the migration time and the m/z value, respectively. The
color density reﬂects the difference in intensity between the averaged
control and oral cancer samples. Black circles indicate peaks that are
signiﬁcantly different between healthy control and oral cancer
samples (P\0.05; Steel–Dwass test). The small linked ﬁgures
include overlaid electropherograms of control (blue) and oral cancer
samples (red)
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123concentration of putrescine and cadaverine are decreased in
cancer patients undergoing radiotherapy but remain higher
than those in healthy individuals (Khuhawar et al. 1999).
There were no signiﬁcant differences in urinary polyamine
levels between the healthy individuals and breast cancer
patients; however, the levels of putrescine, spermine and
other metabolites were signiﬁcantly higher in patients with
breast cancer (Byun et al. 2008). Oral polyamine levels are
also affected by periodontitis and gum healing (Silwood
et al. 2002). We found that the levels of ornithine and
putrescine were higher in patients with breast or pancreatic
cancer, and were markedly higher in patients with oral
cancer, than in our healthy controls, while there was no
signiﬁcant difference between patients with periodontal
disease and the controls. Although the quantitative level of
polyamines is associated with regulation of tumor growth
and with periodontitis, our results indicate that salivary
polyamines are affected by the cancer type and by peri-
odontitis, and that their levels were markedly higher in
patients with oral cancer.
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Fig. 2 Representative dot plots for the relative area of detected
metabolites in samples from all groups. The colored dots denote
healthy controls (blue), oral (red), breast (pink), pancreatic cancer
(green), and periodontal disease (purple). The Y- and X-axes denote
the relative peak area (no units) and the group name, respectively. The
horizontal, center long bars and the short top/bottom bars indicate the
means and standard deviations, respectively. The stars indicates
* P\0.05, ** P\0.01, and *** P\0.001 (Steel–Dwass test).
Only metabolites showing a signiﬁcant difference between oral
cancer and controls at P\0.001 and matched with standard library
are displayed. The dot plots of the other metabolites are shown in
Supplementary Fig. S1
Fig. 3 Score plots of principal
components (PC) analyses. The
subjects in all groups are shown
in 3-dimensional (a) and
2-dimensional (b) plots without
outliers. The cumulative
proportions of the ﬁrst, second
and third PCs (PC1, PC2, and
PC3) were 44.8, 57.6 and
67.0%. The same analyses
presented for all datasets are
shown in Supplementary
Fig. S2
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123In addition to polyamines, the level of tryptophan
(Carlin et al. 1989), which is increased in oral and pan-
creatic cancer, is a direct marker for tumor development. In
terms of an indirect connection between the detected
metabolites and human cancer, the repeat peptide Pro-Pro-
Gly, which is expressed at high levels in breast cancer, is
an inhibitor of matrix metalloproteinase-2 (MMP-2, gela-
tinase A), which plays an important role in tumor invasion
and metastasis (Jani et al. 2005). The expression levels of
the amino acid transporters ACST2 and LAT1 are elevated
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Fig. 4 ROC curve analysis of
the ability of salivary
metabolites to discriminate
between samples from patients
with a oral (n = 69), b breast
(n = 30) or c pancreatic cancer
(n = 18), and d samples from
patients with periodontal
diseases (n = 11) and the
controls (n = 87). The solid
(red) and dotted (blue) ROC
curves were obtained using the
complete data as a training set
and with a tenfold cross-
validation, respectively. Using a
cut-off probability of 50%, the
calculated area under the ROC
curves were 0.865 (0.810) for
oral, 0.973 (0.881) for breast
and 0.993 (0.944) for pancreatic
cancer, and 0.969 (0.954) for
periodontal diseases. The non-
parenthetic values were
obtained with the full-training
data and parenthetic values by
tenfold cross-validation
Fig. 5 Heat map of 57 peaks showing signiﬁcantly different levels
(P\0.05; Steel–Dwass test) between control samples (n = 87) and
samples from patients with at least one disease (n = 128). Each row
shows data for a speciﬁc metabolite and each column shows an
individual. The colors correspond to the relative metabolite areas that
were converted to Z-scores
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123in primary human cancers, and cancer cells optimize their
metabolic pathways by activating the extra- to intracellular
exchange of amino acids. Peptides and acids are derived
from various sources, such as fragmented proteins, and the
saliva metabolome proﬁles comprising these compounds
may reﬂect the integrated results.
A signiﬁcantly decreased level of arginine was observed
in plasma samples from several cancers including breast,
colonic and pancreatic cancer, which might be due to
increased uptake of arginine by tumor tissues with high
arginase activity (Vissers et al. 2005). However, salivary
arginine was hardly changed, and there were no differences
among the groups (Supplementary Fig. S3 and Table S2).
A trend for decreasing levels of amino acids, including
leucine, isoleucine, valine and alanine, has been reported in
pancreatic cancer samples (Fang et al. 2007). The levels of
amino acids in breast cancer tissue samples showed similar
patterns, with low levels of isoleucine, leucine, lysine and
valine (Yang et al. 2007). The decreased amino acid levels
appear to be the result of enhanced energy metabolism or
upregulation of the appropriate biosynthetic pathways, and
required cell proliferation in cancer tissues. However, the
observed salivary amino acid levels showing signiﬁcant
differences in the cancer groups (in Table 2) were higher
than in the controls. The heterogeneous systems that
transport amino acids from blood to saliva via the salivary
gland, such as kinetic differences, or the dependence or
independence of small ions such as potassium and sodium
(Mann and Yudilevich 1987), altered the concentration of
these ions because of water movement through the para-
cellular route (Melvin 1999) or channels (Ishikawa and
Ishida 2000). Metabolism in the salivary gland itself might
also play a major contribution to the differences in proﬁles
between saliva and blood. Further validation of these
ﬁndings by comparing saliva proﬁles with blood and tissue
proﬁles is needed to understand the reason for the different
saliva amino acid proﬁles.
Choline, a quaternary amine, is an essential nutrient that
is predominantly supplied by the diet, and choline-con-
taining metabolites are important constituents of
phospholipid metabolism of cell membranes and are
associated with malignant transformation, such as breast,
brain and prostate cancers (Ackerstaff et al. 2003). Mag-
netic resonance spectroscopy (MRS) is routinely used to
quantify choline-based metabolism in malignancies such as
head and neck cancer and breast cancers (Bolan et al.
2003). Choline is highly metabolized in tumors to phos-
phocholine and is also highly oxidized to betanine; hence,
the low concentration of choline and high concentrations of
phosphocholine and betaine (Katz-Brull et al. 2002) were
observed. Furthermore, the levels of choline metabolites
were higher in tumors than in benign lesions or normal
tissues (reviewed in Haddadin et al. 2009). In tumor cells,
an excessive increase in plasma choline levels in patients
with breast cancer was also shown (Katz-Brull et al. 2001).
Aberrant choline metabolism can be explained as a result
of enhanced membrane synthesis and degradation, which
represent excessive proliferation of cancer cells. Pancreatic
cancer tissue had a unique proﬁle showing decreased levels
of phosphocholine and glycerophosphocholine, but not
choline (Fang et al. 2007). We found that the levels of
phosphocholine (Supplementary Fig. S3 and Table S2) and
glycerophosphocholine (Table 2) were increased in the
saliva samples from oral cancer patients and were
decreased in the other groups.
Creatine phosphate acts as a store for high-energy
phosphates. Therefore, its concentration might be altered in
energy-demanding tissues (Maheshwari et al. 2000). Pre-
vious studies showed an increase in the choline-creatinine
ratio in tumor tissues and in the serum of patients with
OSCC (Maheshwari et al. 2000; Tiziani et al. 2009). Cre-
atine is converted to creatine phosphate by creatine kinase.
Increased creatine phosphate levels were also found in other
tumors, such as breast and gastrointestinal tract tumors. In
our study, the salivary choline level was signiﬁcantly higher
in subjects with oral and pancreatic cancers (P = 2.30 9
10
-5 and P = 1.91 9 10
-4, respectively; Steel–Dwass
test), but not in the other groups. Therefore, the salivary
choline–creatinine ratio showed oral cancer-speciﬁc ele-
vation (Supplementary Table S2 and Fig. S3). However,
this ﬁnding needs to be interpreted with care because cho-
line is a nutrient present in most foods.
Compared with oral cancer, breast and pancreatic
tumors are physically remote from the oral cavity. There-
fore, it can be questioned why salivary metabolite proﬁles
reﬂect the aberrant localized tumour metabolism. Systemic
bioﬂuids, such as blood and lymph ﬂuid, are one of the
routes that readily bypass these tumors and the salivary
gland, which blends saliva with contaminating blood.
Several metabolites in tumor tissues, such as lactate, which
is derived from tumor exposed to hypoxia, were altered
both with and without metastasis (Hirayama et al. 2009;
Walenta et al. 2000). Although abnormal arginine levels in
breast cancer without metastasis were observed, the same
metabolic changes were shown in a pooled group of
patients with colonic and pancreatic cancer with/without
metastasis (Vissers et al. 2005). In OSCC patients without
metastasis from the primary tumor, cancer-speciﬁc changes
in serum and salivary mRNA levels (Li et al. 2006; Pick-
ering et al. 2007) and blood metabolome levels (Tiziani
et al. 2009; Zhou et al. 2009) were shown. Although this
does not constitute direct proof that the aberration in sali-
vary metabolites is attributed to a remote tumor, evidence
that the salivary metabolite proﬁles reﬂects the systemic
and localized tumor status or its response to chemothera-
pies, such as breast and lung cancer, has accumulated
90 M. Sugimoto et al.
123(Emekli-Alturfan et al. 2008; Gao et al. 2009; Harrison
et al. 1998; Streckfus et al. 2006, 2008). Although previous
studies have demonstrated an increase in choline metabo-
lites in blood in various cancers, the increase in choline
metabolites in oral cancer patients in study indicate that the
transportation of these metabolites from the blood to the
saliva through the salivary gland is low, even though their
levels in blood are elevated. Alternatively, these metabo-
lites were diffused from the oral malignancy to the salivary
gland via a route other than the blood vessel. We
acknowledge that the current study merely mined the data
and showed that the changes in salivary metabolites had
cancer-speciﬁc features. Further biological studies to
compare the metabolite proﬁles obtained concurrently from
saliva, blood and cancer tissue is needed to provide rational
evidence for the systemic metabolite links.
3.3 Bias derived from clinical parameters
We evaluated the metabolite bias introduced by relevant
clinical parameters (age, gender, race and ethnicity). The
PCA score plots showed poor separation between male and
female subjects among healthy controls and patients with
oral cancer (Supplementary Fig. S4). Statistical compari-
sons of the relative area are presented in Supplementary
Table S3. Takeda et al. (2009) measured the gender-spe-
ciﬁc differences in salivary metabolites and found that
formate, lactate, propionate and taurine were signiﬁcantly
higher in males. Compared with these metabolites, the
gender-speciﬁc level of taurine, which was the only
metabolite observed in our measurement condition, showed
little difference between the subjects in the control and oral
cancer groups. By contrast, in the control group, tyrosine
and a metabolite at 214.4440 m/z were signiﬁcantly higher
in females than in males (P = 0.0492 and p = 0.0261,
respectively; Mann–Whitney test). In the oral cancer
group, threonine and serine were signiﬁcantly higher in
males and piperidine was higher in females (P = 0.0340,
P = 0.0462, and P = 0.0221, respectively; Mann–Whit-
ney test). Takeda et al. (2009) discussed that these gender-
speciﬁc differences might be attributed to dental care,
hormones such as estrogen, and oral pathogenesis carriers
such as microﬂora. Indeed, infection of the oral environ-
ment with viruses such as human papillomavirus or micro-
organisms is known to be a risk factor for the development
of oral cancer (Meurman and Uittamo 2008). Although we
found that the gender-speciﬁc differences in metabolic
proﬁles differed between the tumor types, the number of
metabolites showing signiﬁcant differences was low, which
implies that the disease-speciﬁc variation is predominantly
embedded in the 57 metabolites identiﬁed here.
In the control and oral cancer groups, the PCA based on
race and ethnicity were visualized using score plots
(Supplementary Fig. S5) and the statistical analytical
results are presented in Supplementary Table S4. In the
control group, there were no signiﬁcant differences
between African-Americans and Caucasians, or African-
Americans and Hispanics. Meanwhile, 11 and 12 signiﬁ-
cantly different (P\0.05; Steel–Dwass test) metabolites
were observed between African-Americans and Asians,
and Asians and Caucasians, respectively. Similarly, the
proﬁles between Asians and Hispanics, and Caucasians and
Hispanics revealed three and seven signiﬁcantly different
metabolites (P\0.05; Steel–Dwass test). Of particular
note, levels of putrescine, proline, glycine and unannotated
metabolites at 118.0864 m/z and 10.05 min were low in
Asians, while the level of burimamide was high in African-
Americans. A country-dependant bias in human urinary
metabolite proﬁles has also been reported elsewhere
(Holmes et al. 2008). In their study, positively charged
metabolites, such as alanine-related metabolites, showed
discriminative characteristics and were correlated with
several dietary factors such as energy intake, dietary cho-
lesterol and alcohol intake. However, in our study, there
were no differences in alanine levels in either the control or
the oral cancer subjects. In the control group, there were no
differences in 34 out of 57 marker candidates among the
race or ethnic groups. In subjects with oral cancer, only a
metabolite at 211.4440 m/z showed a signiﬁcant difference
(P = 0.0386; Steel–Dwass test). Although biases based on
race or ethnicity-were found in the 57 metabolic proﬁles,
the number of the metabolites showing signiﬁcant differ-
ences were less than the number of peaks showing signif-
icant differences in cancer-speciﬁc proﬁles, which implies
that this bias might be more moderate than disease-speciﬁc
differences.
Age-related differences have been reported in a tran-
scriptome study of the salivary gland (Srivastava et al.
2008). The coefﬁcients of regression lines for age and
relative area for all 57 metabolite markers are presented in
Supplementary Table S5. It has been reported that other
commonly used methods for standardization of metabolites
in bioﬂuid yield different statistical results (Schnackenberg
et al. 2007); therefore, consistent decreases or increases in
levels of metabolites among subjects with correlated clin-
ical parameters should be accounted for. In the control
subjects and patients with pancreatic cancer, there was a
positive correlation between metabolites and age, whereas
the opposite was true for patients with oral or breast cancer
or periodontal diseases. Accordingly, it is unlikely that
age is correlated with the concentrations of salivary
metabolites.
Several limitations in this study need to be acknowl-
edged. First, the metabolite proﬁles in saliva might ﬂuc-
tuate to similar or greater levels compared with other omics
proﬁles, such as the proteome and transcriptome, in
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conditions including gingival crevicular ﬂuid and oral
microbiota (reviewed in Fabian et al. 2008). Therefore, the
reproducibility of the sample collection protocol used in
this study should be rigorously veriﬁed under various
conditions. Circadian rhythms in salivary ﬂow rate and
components have been reported (Dawes 1972). Levels of
putrescine and cadaverine, which correlate with oral mal-
odor, were markedly altered during waking time, even in
healthy donors (Cooke et al. 2003). Although, the samples
were collected within a limited period of time in the
morning, levels of these metabolites were generally higher
in patients with most types of cancer in the present study.
The variance in the concentrations of these metabolites
should be validated in future studies. Another external
factor that alters saliva contents is the time-course of
ﬂuoride concentration, which has been tracked, and the
changes in concentrations continued for 30 min after eating
food (Hedman et al. 2006). Therefore, the 1-h period before
sample collection should be evaluated in terms of food
intake. Smoking is also known to affect salivary metabo-
lites such as citrate lactate, pyruvate and sucrose (Takeda
et al. 2009). The metabolites identiﬁed in this study could
not be compared with these metabolites because they were
not positively charged in our measurement condition.
Therefore, the proﬁles of positively charged metabolites
should be explored in further analyses.
Second, the sample sizes, particularly the number of
patients with breast or pancreatic cancer or periodontal
diseases, were relatively small. A larger cohort, including
samples from an independent institute, would allow for
statistical comparisons with greater power and a more
rigorous validation. In addition, samples from patients with
systemic diseases showing similar symptoms, such as oral
leukoplakia and oral cancer (Zhou et al. 2009), chronic
pancreatitis and pancreatic cancer (Fang et al. 2007;
Kojima et al. 2008), should be compared with evaluate the
sensitivity and speciﬁcity of the detected metabolites. In
this study, the patients’ age was collected for all samples
and only a few additional parameters, namely sex and race,
or ethnic group, were collected for the control and oral
cancer group. Analyses and validation studies taking into
account the complete clinical and pathological parameters,
including menopausal status, estrogen and progesterone
receptors for breast cancer, and risk factors including
smoking and alcohol drinking for oral cancers are essential
before actual diagnostic application of the classiﬁcation
model obtained in this study. In this study, although we
used stepwise feature selection and an MLR model to
identify classiﬁers, other feature selection and classiﬁcation
methods are also applicable, such as regression tree models
(Li et al. 2004, 2006) and concurrent use of ANN with
SVM (Ayers et al. 2004). Instead of developing a
classiﬁcation model only based on the salivary metabolome
proﬁles of matched subjects, the construction of a marker
model incorporating related clinical features or risk factors
and biomarkers can be used to visualize the probability of a
speciﬁc diseases status; for example, nomograms are a
commonly used strategy (Brennan et al. 2004; Gross et al.
2008; Katz et al. 2008).
A metabolomic study using serum samples from patients
with oral cancer showed stage-speciﬁc proﬁles (Tiziani
et al. 2009). The proﬁles obtained in this study were simply
categorized into the type of cancer. Therefore, future
studies are needed that integrate histological and clinical
features. Simultaneous analyses of the metabolic proﬁles in
blood and tissue collected from the same patients are also
needed to track the biological sources of the disease-spe-
ciﬁc signatures in salivary metabolite proﬁles. Although
there are still several limitations to be addressed, the
methodology used in this study to detect salivary metabo-
lite proﬁles are not limited to early diagnosis but offer the
potential to aid the characterization of malignant neo-
plasms or tumors by integrating histological or clinical
features, such as staging.
4 Concluding remarks
This is the ﬁrst study to comprehensively analyze salivary
metabolites and to identify metabolic proﬁles speciﬁc to
oral, breast and pancreatic cancers. A larger number of
patient samples, particularly those from different institutes,
and additional clinical variables are needed for further
validation and future clinical application of our method. In
addition, integrating the knowledge obtained from other
omics studies may help us to understand the biological
basis of these disease-speciﬁc metabolic proﬁles.
In conclusion, our study has demonstrated that CE-TOF-
MS can readily and effectively be applied to salivary
metabolomics. We have proposed an alternative use for
salivary diagnosis to be applied for the detection of oral,
breast and pancreatic cancers.
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